Mary Coleman
Mary Coleman is an Executive Vice President at Compass Lexecon. Dr. Coleman received her Ph.D. in Economics from Stanford University.
From November 2001 until March 2004, Dr. Coleman was the Deputy Director for Antitrust in the Bureau of Economics of the Federal Trade Commission. During her tenure at the FTC, Mary was instrumental in the efforts in the Bureau of Economics to increase the empirical content of antitrust investigations at the FTC and to increase the cooperation between the economic and legal staffs. Dr. Coleman also worked extensively in the cooperative efforts between the FTC and the EU and other foreign jurisdictions.
From May 2004 to August 2009, Mary was a Managing Director at LECG, LLC. Mary also worked at LECG from 1993 to 2001 and was a Principal from 1999 to 2001. From 1990 to 1993, Dr. Coleman served as a staff economist at the Federal Trade Commission, including as lead economist on the Commission’s investigation of Microsoft.
Mary Coleman
Jan 15, 2009
A couple of weeks ago, I posted a blog discussing the FTC’s complaint against Ovation. One of the interesting factors of that complaint was the FTC’s decision to seek disgorgement of profits allegedly improperly gained as a result of the challenged acquisition. The FTC has only infrequently sought disgorgement in antitrust matters and it is ... Disgorgement and Damages in Ovation
Mary Coleman
Dec 29, 2008
On December 16, 2008, the FTC filed a complaint against Ovation Pharmaceuticals that challenged its 2006 acquisition of the drug Neoprofen from Abbott. (The acquisition had fallen beneath the HSR thresholds and thus was not subject to an HSR investigation prior to consummation). While the complaint and case itself raises some interesting issues which I ... Economic Issues in the Ovation Complaint
